PRNewsWire
15 Jun 2026, 06:52 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Akeso has enrolled the first patient in a Phase Ib/II study testing AK138D1 (a next-gen HER3 ADC) as a monotherapy or in combination with ivonescimab for advanced breast cancer. — Advancing a candidate into Phase Ib/II for a high-prevalence indication like breast cancer represents a tangible step toward commercialization and value creation.
+0.40Early-stage clinical data for AK138D1 indicates robust anti-tumor activity in breast cancer with low hematologic toxicity and no observed interstitial lung disease (ILD). — Overcoming the common toxicity hurdles (specifically ILD) associated with traditional ADCs increases the probability of clinical success and competitive differentiation.
+0.30Akeso is executing an 'IO2.0 + ADC2.0' strategy, leveraging its proprietary bispecific antibody platforms and next-generation ADCs to target breast cancer subtypes HR+/HER2- and TNBC. — The strategic pivot toward combination therapies in high-unmet-need segments suggests a scalable platform approach rather than a single-asset bet.
+0.20Continue reading
6 related stories
Search tags
Which stocks this story touches
The company announced the first patient enrollment in a Phase Ib/II study for its next-generation ADC and highlighted a strong pipeline of innovative oncology therapies.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
18h ago
